SCHEMBL1708492

SCHEMBL1708492

CON(C)C(=O)Cc1c(F)cccc1F

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 1/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ ALDH1A1 P00352 3/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ HDAC4 P56524 1/20 0.39
▸ HDAC6 Q9UBN7 1/20 0.39
▸ KMT2A Q03164 3/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ TRPM8 Q7Z2W7 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ TP53 P04637 1/20 0.35
▸ MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14814503 0.89 SMN1; SMN2 (0.56) SMN1; SMN2ALDH1A1KDM4EKMT2ARXFP1
SCHEMBL15271226 0.86 HDAC4 (0.39) GRM5SMN1; SMN2HDAC4HDAC6KMT2A
SCHEMBL8572761 0.82 GRM5 (0.42) GRM5SMN1; SMN2ALDH1A1KDM4EKMT2A
SCHEMBL1668464 0.81 ALDH1A1 (0.45) ALDH1A1KDM4EKMT2APOLBMEN1
SCHEMBL38660431 0.79 KMT2A (0.39) KDM4EHDAC4HDAC6KMT2ATDP1
SCHEMBL13032597 0.79 CA12 (0.43) SMN1; SMN2ALDH1A1POLB
SCHEMBL1515850 0.77 HDAC4 (0.45) ALDH1A1KDM4EHDAC4HDAC6KMT2A
SCHEMBL1707313 0.76 TAAR1 (0.46) HDAC4HDAC6KMT2ATRPM8MEN1
SCHEMBL23977073 0.75 EED (0.36) GRM5SMN1; SMN2ALDH1A1KDM4EKMT2A
SCHEMBL9985451 0.74 SMN1; SMN2 (0.56) SMN1; SMN2ALDH1A1KDM4EKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1981877-B1 N-HYDROXYACRYLAMIDE COMPOUNDS ASTELLAS PHARMA INC (JP) 2012-04-18 — — EP disclosed
US-7750155-B2 Pyrazinyl hydroxyacrylamide compounds having an inhibitory effect on the activity of histone deacetylase ASTELLAS PHARMA INC. (JP) 2010-07-06 — — US disclosed
US-20090054465-A1 N-HYDROXYACRYLAMIDE COMPOUNDS ASTELLA PHARMA INC. (JP) 2009-02-26 — — US disclosed
EP-1981877-A1 N-HYDROXYACRYLAMIDE COMPOUNDS Astellas Pharma Inc. (JP) 2008-10-22 — — EP disclosed
WO-2007091703-A1 N-HYDROXYACRYLAMIDE COMPOUNDS ASTELLAS PHARMA INC. (JP) 2007-08-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054465-A1 N-HYDROXYACRYLAMIDE COMPOUNDS HDAC1, HDAC6, HDAC5 GRM5 1892/4885SMN1; SMN2 208/4885ALDH1A1 266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback